Details

Autor(en) / Beteiligte

• Álvarez, Patricia
• Ramiro-Cortijo, David
• Montes, María Teresa
• Moreno, Bárbara
• Calvo, María V.
• Liu, Ge
• Esteban Romero, Ana
• Ybarra, Marta
• Cordeiro, Malaika
• Clambor Murube, Marina
• Valverde, Eva
• Sánchez-Pacheco, Aurora
• Fontecha, Javier
• Gibson, Robert
• Saenz de Pipaon, Miguel

Titel

Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants

Ist Teil von

• Frontiers in pediatrics, 2022-08, Vol.10, p.947221-947221

Ort / Verlag

Frontiers Media S.A

Erscheinungsjahr

2022

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Objective To evaluate changes in blood long-chain polyunsaturated fatty acid (LCPUFA) and oxylipin concentrations in very preterm infants from birth to 36 weeks’ postmenstrual age (WPA) after providing an emulsified arachidonic acid (ARA):docosahexaenoic acid (DHA) supplement at two different concentrations. Study design This prospective, randomized trial assigned infants to receive a supplement (1) 80:40 group (80 mg/kg/day ARA and 40 mg/kg/day DHA, n = 9) or (2) 120:60 group (120 mg/kg/day ARA and 60 mg/kg/day DHA, n = 9). Infants received supplement daily from birth until 36 WPA. At baseline, 21 days of life and 36 WPA, the LCPUFAs were measured in plasma by gas chromatography/mass spectrophotometry. Additionally, LCPUFAs and oxylipins were analyzed in whole blood by ultra-high-performance liquid chromatography-tandem mass spectrometry. Furthermore, a sample of oral mucosa was obtained to analyze single-nucleotide polymorphism located in the FADS1 gene by PCR. Results Gestational age was similar between groups (80:40 = 28 +6 [27 +3 ; 30 +3 ] completed weeks + days ; 120:60 = 29 +6 [27 +3 ; 30 +5 ] completed weeks + days , p = 0.83). At 36 WPA, the change in plasma ARA was significantly different between groups (80:40 group = 0.15 [−0.67; 0.69] %nmol, 120:60 = 1.68 [1.38; 3.16] %nmol, p = 0.031). In whole blood, the levels of ARA-derived oxylipins (5-, 8-, 9-, 11-, 15-HETE and 8,9-EET) and EPA-derived oxylipins (18-HEPE) significantly increase from baseline to 36 WPA in the 120:60 group than the 80:40 group. Conclusion Supplementation at high doses (120:60 mg/kg/day) increased levels of ARA, and EPA- and ARA-derived oxylipins compared to low doses (80:40 mg/kg/day). Differences were detected in EPA metabolites without a significant increase in plasma DHA.